Compare Regeneron Pharmaceuticals Inc (REGN) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Upwork Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while Upwork Inc trades at $8.31 (market cap $1.04B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 80.2× Upwork Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Upwork Inc pays none. Which is the better fit depends on your goals.
| REGN | UPWK | |
|---|---|---|
Market Cap | $83.43B | $1.04B |
Sector | Health | Industrials |
52-Week High | $852.03 | $22.11 |
52-Week Low | $555.51 | $7.84 |
Enterprise Value | $78.14B | $802.40M |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Upwork (UPWK) is trading at $8.32, down 5.35% on the day, with a bearish technical signal and recent earnings volatility. The company maintains strong profitability metrics including a 77.21% gross margin and 12.93% net income margin, though Q2 2026 earnings beat was overshadowed by weak guidance. Recent news highlights multiple securities fraud investigations alongside AI integration developments.
The stock presents a mixed outlook with attractive valuation multiples (P/E 10.67, P/S 1.44) but faces headwinds from AI disruption and legal scrutiny. Analyst consensus leans bullish with a $9.00 price target, though technical indicators suggest near-term pressure with support at $8.00.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
